Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thank you LXGTF :)
LXGTF Article by Jonathan Maltz, "What is Endothelial Function..." : https://lexingtonbiosciences.com/news/endothelial-function-important-health
LXGTF Corporate Profile: https://lexingtonbiosciences.com/investors/corporate-profile/
Let see some move here now!
Big Bigger LXGTF!
The only bad thing is their name :)
THE FUTURE IS OUR!
GREAT!
great NEWS
it must break in one moment!
Did you see the amazing LXGTF video: https://vimeo.com/183611304
NEW HERE? Start your dd from the LXGTF website:
https://lexingtonbiosciences.com/
The FACTS ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
WHY is LXGTF better?
Knowing the core health of the cardiovascular system is critical to preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only partial indicators of cardiovascular health.
STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
can we see it today? go LXGTF!
thank you for this viewpoint
good morning guys, exited for today!
not bad
this is where we going in!
we are in good closure
thank you SPM
this will be cool
HeartSentry Technology rectifies this alarming situation:
Quote:
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry.
For more information about the company please visit:
https://lexingtonbiosciences.com/.
Eric Willis
CEO & Director
we want more!!! :)
than you, great
Green coming .43
LXGTF save lifes!
Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
WHY is LXGTF better then others?
Knowing the core health of the cardiovascular system is critical to preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only partial indicators of cardiovascular health.
Maltz is super smart guy!
very clear and victorious schedulle
Wow amazing article..
not bad idea...
thanks for the youtube version love it
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
LIKE THE SUMMARY LXGTF : Lexington BioSciences (CSE: LNB) (OTCQB: LXGTF) is developing
the HeartSentry, a new non-invasive diagnostic tool for accurately measuring
and monitoring cardiovascular health.
• The HeartSentry measures the function of the endothelium – the critical inner
lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the
company.
• Lexington is in final stages of releasing the product into clinical studies for FDA
approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general
practitioners, and ultimately patients first line evaluation of cardiovascular
health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized
medicine.
WoW! Blood pressure monitor market forecast to exceed $2.6 billion by 2020
All aprovals in process! HEARTSENTRY is an FDA regulated product that uses the expedited 510(k)
premarket approval process
HeartSentry FDA Classification:
• Class: II
• Panel: Cardiovascular
Likely HeartSentry Predicates
• Itamar Medical EndoPat 2000
• iHealth Wireless Blood Pressure Monitor
International market approvals are also being pursued.